tiprankstipranks
Thermo Fisher Scientific (DE:TN8)
:TN8
Holding DE:TN8?
Track your performance easily

Thermo Fisher Scientific (TN8) Stock Price & Analysis

6 Followers

TN8 Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Financial StrategyThermo Fisher’s one-stop platform enables cross-selling within internal segments to achieve inter-segment synergy.
Growth PotentialMultiple growth drivers bode well for the long-term industry outlook, including the potential recovery of healthcare funding driven by interest rate cuts.
Market LeadershipThermo Fisher, distinguished by its extensive portfolio of products and services, stands as a global leader in life science services.
Bears Say
Financial PerformanceAdjusted gross margin contracted year-over-year and quarter-over-quarter, slightly below management's expectations.
Market OutlookThere is caution regarding the 4Q revenue guidance, which might be under pressure.
Sector ChallengesPharma and Biotech spending remains muted, showing a slower recovery in these key markets.
---

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.10%24.28%0.49%56.72%
0.49% Other Institutional Investors
56.72% Public Companies and Individual Investors

TN8 FAQ

What was Thermo Fisher Scientific’s price range in the past 12 months?
Thermo Fisher Scientific lowest stock price was €469.65 and its highest was €575.60 in the past 12 months.
    What is Thermo Fisher Scientific’s market cap?
    Thermo Fisher Scientific’s market cap is €202.39B.
      When is Thermo Fisher Scientific’s upcoming earnings report date?
      Thermo Fisher Scientific’s upcoming earnings report date is Jan 30, 2025 which is in 15 days.
        How were Thermo Fisher Scientific’s earnings last quarter?
        Thermo Fisher Scientific released its earnings results on Oct 23, 2024. The company reported €5.1 earnings per share for the quarter, beating the consensus estimate of €5.063 by €0.037.
          Is Thermo Fisher Scientific overvalued?
          According to Wall Street analysts Thermo Fisher Scientific’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Thermo Fisher Scientific pay dividends?
            Thermo Fisher Scientific pays a N/A dividend of €1.511 which represents an annual dividend yield of 0.29%. See more information on Thermo Fisher Scientific dividends here
              What is Thermo Fisher Scientific’s EPS estimate?
              Thermo Fisher Scientific’s EPS estimate is 5.77.
                How many shares outstanding does Thermo Fisher Scientific have?
                Thermo Fisher Scientific has 382,500,270 shares outstanding.
                  What happened to Thermo Fisher Scientific’s price movement after its last earnings report?
                  Thermo Fisher Scientific reported an EPS of €5.1 in its last earnings report, beating expectations of €5.063. Following the earnings report the stock price went down -2.733%.
                    Which hedge fund is a major shareholder of Thermo Fisher Scientific?
                    Currently, no hedge funds are holding shares in DE:TN8
                    ---

                    Company Description

                    Thermo Fisher Scientific

                    Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery, and diagnostics. It operates through the Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services segments. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.
                    ---

                    TN8 Earnings Call

                    Q3 2024
                    0:00 / 0:00
                    Earnings Call Sentiment|Neutral
                    The earnings call highlighted strong financial performance and strategic advancements, including innovation and successful M&A integration. However, challenges in key segments such as pharma and biotech, as well as flat growth in diagnostics and healthcare, present headwinds. The company's proactive measures and raised guidance indicate optimism, but the balanced nature of highlights and lowlights suggests cautious optimism.Read More>
                    ---

                    TN8 Revenue Breakdown

                    53.76%53.76%23.28%16.95%10.28%
                    53.76% Laboratory Products and Biopharma Services
                    23.28% Life Sciences Solutions
                    16.95% Analytical Instruments
                    10.28% Specialty Diagnostics
                    tipranks
                    ---

                    TN8 Stock 12 Month Forecast

                    Average Price Target

                    €643.00
                    ▲(18.05% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"492":"€492","537":"€537","582":"€582","627":"€627","672":"€672"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":671.83512,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€671.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":643,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€643.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":567.9531,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€567.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[492,537,582,627,672],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"Jan<br/>2025","25":"Jan<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500.3,513.4950092307693,526.6900184615384,539.8850276923076,553.0800369230769,566.2750461538461,579.4700553846153,592.6650646153846,605.8600738461538,619.0550830769231,632.2500923076923,645.4451015384615,658.6401107692307,{"y":671.83512,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500.3,511.2769230769231,522.2538461538462,533.2307692307693,544.2076923076924,555.1846153846154,566.1615384615385,577.1384615384616,588.1153846153846,599.0923076923077,610.0692307692308,621.0461538461539,632.0230769230769,{"y":643,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500.3,505.5040846153846,510.7081692307692,515.9122538461538,521.1163384615385,526.320423076923,531.5245076923077,536.7285923076923,541.9326769230769,547.1367615384615,552.3408461538461,557.5449307692307,562.7490153846153,{"y":567.9531,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":493.742,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":496.634,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":528.745,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":529.394,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":518.417,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":506.7,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":572.709,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":553.136,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":556.489,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":503.528,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":500.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Thermo Fisher
                    Danaher
                    Agilent
                    Illumina
                    Mettler-Toledo
                    Bio-Rad Laboratories
                    Waters

                    Best Analysts Covering TN8

                    1 Year
                    1 Year Success Rate
                    19/20 ratings generated profit
                    95%
                    1 Year Average Return
                    +23.31%
                    upgraded a buy rating 12 months ago
                    Copying Jack Meehan's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +23.31% per trade.
                    Popular Stocks
                    ---
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis